Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 1
2017 1
2019 2
2020 1
2021 1
2022 1
2023 2
2024 1
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: ZWI-ZW191-101
Page 1
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Moore KN, et al. Cancer. 2017 Aug 15;123(16):3080-3087. doi: 10.1002/cncr.30736. Epub 2017 Apr 25. Cancer. 2017. PMID: 28440955 Free PMC article. Clinical Trial.
BACKGROUND: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate receptor alpha (FRalpha). In this phase 1 dose-escalation study, the authors investigated IMGN853 in patients with …
BACKGROUND: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate …
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Moore KN, et al. Gynecol Oncol. 2024 Dec;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Epub 2024 Oct 25. Gynecol Oncol. 2024. PMID: 39461270
OBJECTIVE: Mirvetuximab soravtansine-gynx (MIRV) is a novel antibody-drug conjugate targeting folate receptor alpha (FRalpha), which is overexpressed in epithelial ovarian cancer (EOC), with limited expression on normal tiss …
OBJECTIVE: Mirvetuximab soravtansine-gynx (MIRV) is a novel antibody-drug conjugate targeting folate receptor …
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, Allred S, Huang LY, Hahn J, Gahnberg K, Treuting PM, Trueblood ES, Gosink JJ, Thurman R, Wo S, Spahr K, Haass EJ, Snead K, Miller D, Padilla M, Smith AJ, Frantz C, Schrum JP, Nazarenko N, Gardai SJ. Gray E, et al. J Immunother Cancer. 2023 Oct;11(10):e007572. doi: 10.1136/jitc-2023-007572. J Immunother Cancer. 2023. PMID: 37793853 Free PMC article.
BACKGROUND: SGN-B7H4V is a novel investigational vedotin antibody-drug conjugate (ADC) comprising a B7-H4-directed human monoclonal antibody conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine ci …
BACKGROUND: SGN-B7H4V is a novel investigational vedotin antibody-drug conjugate (ADC) comprising a B7-H4-directed huma …
Targeting NaPi2b in ovarian cancer.
Banerjee S, Drapkin R, Richardson DL, Birrer M. Banerjee S, et al. Cancer Treat Rev. 2023 Jan;112:102489. doi: 10.1016/j.ctrv.2022.102489. Epub 2022 Nov 14. Cancer Treat Rev. 2023. PMID: 36446254 Free article. Review.
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. ...Emerging data from phase 1 and 2 clinical trials in ovarian cancer …
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heav …
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.
Zhong J, Wu L, Song Z, Xing N, Cui J, Li X, Fei K, Tang D, Dang Q, Chen L, Liu T, Liu C, Li Y, Zhang S, Han X, Xiao J, Guo F, Yan M, Xu H, Yuan C, Zhong J, Liu R, Qu X, Wu S, Jiang S, Yang Y, Zhang P, Guo H, Wang C, Xie Q, Lin Z, Wang S, Wang J. Zhong J, et al. Cancer Cell. 2025 Dec 8;43(12):2268-2281.e3. doi: 10.1016/j.ccell.2025.09.012. Epub 2025 Oct 23. Cancer Cell. 2025. PMID: 41135519 Clinical Trial.
This study is a first-in-human, three-stage, phase 1 trial (NCT05154604) designed to evaluate the trophoblast cell-surface antigen 2 (TROP-2)-targeted antibody-drug conjugate SHR-A1921 (1.5-6.0 mg/kg every 3 weeks) in 391 patients with pretreate …
This study is a first-in-human, three-stage, phase 1 trial (NCT05154604) designed to evaluate the trophoblast cell-surface ant …
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.
Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, Piha-Paul SA, Friedman CF, Satoh T, Okamoto N, Singh J, Yoshizuka N, Windish HP, Qian M, Tran BP, Doi T. Johnson ML, et al. Lancet Oncol. 2026 Apr;27(4):491-501. doi: 10.1016/S1470-2045(25)00733-8. Lancet Oncol. 2026. PMID: 41926962 Clinical Trial.
BACKGROUND: Ifinatamab deruxtecan is a novel B7-H3-directed antibody-drug conjugate that leverages the clinically validated deruxtecan technology. We report dose-escalation results from a trial of ifinatamab deruxtecan in patients with solid tumours. METHODS: …
BACKGROUND: Ifinatamab deruxtecan is a novel B7-H3-directed antibody-drug conjugate that leverages the clinically valid …
Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D, Cristea M. Stewart D, et al. Curr Opin Obstet Gynecol. 2019 Feb;31(1):18-23. doi: 10.1097/GCO.0000000000000515. Curr Opin Obstet Gynecol. 2019. PMID: 30531606 Review.
PURPOSE OF REVIEW: Antibody drug conjugates (ADC) are a novel class of cancer therapeutics, delivering cytotoxic therapy directly to cancer cells, and show promise in the management of platinum-resistant ovarian cancer. Herein we summarize the ADC landscape currentl …
PURPOSE OF REVIEW: Antibody drug conjugates (ADC) are a novel class of cancer therapeutics, delivering cytotoxic therapy directly to cancer …
Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion.
Matuszewska L, Cooper C, Sattarova V, Chanbour W, Meyer E, Rashidi V. Matuszewska L, et al. Am J Ophthalmol Case Rep. 2025 Jun 28;39:102375. doi: 10.1016/j.ajoc.2025.102375. eCollection 2025 Sep. Am J Ophthalmol Case Rep. 2025. PMID: 40678735 Free PMC article.
PURPOSE: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23. OBSERVATIONS: A 47-year-old female with a history of advanced recurrent serous ovarian …
PURPOSE: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugat …
Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.
Bekheet F, Ashland M, Reyes R, Dorigo O, Karam A, Chen CT. Bekheet F, et al. Immunotherapy. 2025 Sep;17(13):921-925. doi: 10.1080/1750743X.2025.2561398. Epub 2025 Sep 19. Immunotherapy. 2025. PMID: 40970869
Here, we present the experience of a patient with platinum-resistant ovarian carcinoma who achieved a durable partial response on a phase 1 clinical trial of an anti-CD25 antibody-drug conjugate combined with pembrolizumab. ...We report here a c …
Here, we present the experience of a patient with platinum-resistant ovarian carcinoma who achieved a durable partial response on a phase …
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.
Hayato S, Hamuro L, Shimizu T, Yonemori K, Nishio S, Yunokawa M, Yoshida T, Nishio M, Matsumoto K, Takehara K, Hasegawa K, Kozuki T, Hirashima Y, Kato H, Miura T, Nomoto M, Zhao Y, Zhu L, Yasuda S. Hayato S, et al. J Clin Pharmacol. 2025 Jun;65(6):751-762. doi: 10.1002/jcph.6187. Epub 2025 Jan 24. J Clin Pharmacol. 2025. PMID: 39853764 Free PMC article. Clinical Trial.
The first-in-human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum-resistant ovarian and non-small cell lung cancer. ...
The first-in-human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in …
15 results